Peptide Drugs Deltalicin and Semax Improve Lipid Metabolism in Diabetic Rats
Background
Diabetes Mellitus is a chronic metabolic disease often accompanied by severe lipid metabolism disorders, including elevated total cholesterol, triglycerides, and LDL (low-density lipoprotein), alongside reduced HDL (high-density lipoprotein). These imbalances contribute significantly to cardiovascular complications in diabetic patients. This study investigated whether the peptide drugs deltalicin and Semax could effectively correct these lipid abnormalities in an experimental model of diabetes.
Results
All tested compounds—deltalicin, Semax, and sulodexide—demonstrated corrective effects on lipid metabolism disorders in the diabetic rats. They consistently led to a decrease in total cholesterol, triglycerides, LDL concentration, and the index of atherogenicity, while simultaneously increasing HDL concentration. Deltalicin exhibited a more potent effect on lipid metabolism compared to both sulodexide and Semax, manifesting in a significant decrease in total cholesterol and LDL concentration, as well as a more pronounced improvement in the index of atherogenicity.
Why It Matters
This study highlights the potential of peptide drugs like deltalicin as novel therapeutic agents for managing diabetic dyslipidemia. The finding that deltalicin was more potent than existing treatments suggests it could be a superior option for mitigating cardiovascular risk factors in patients with diabetes. Future research should focus on elucidating the precise mechanisms of action and progressing towards human clinical trials to confirm these promising effects.